Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Cash & Equivalents data on record, last reported at $37.6 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 1.68% year-over-year to $37.6 million; the TTM value through Jun 2025 reached $37.6 million, up 1.68%, while the annual FY2022 figure was $43.1 million, N/A changed from the prior year.
  • Cash & Equivalents reached $37.6 million in Q2 2025 per ZNTL's latest filing, down from $41.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $266.6 million in Q2 2023 and bottomed at $30.6 million in Q1 2022.
  • Average Cash & Equivalents over 4 years is $67.1 million, with a median of $41.3 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 383.39% in 2023, then plummeted 86.13% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $43.1 million in 2022, then soared by 157.15% to $110.8 million in 2023, then crashed by 62.69% to $41.3 million in 2024, then decreased by 9.01% to $37.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $37.6 million in Q2 2025, $41.3 million in Q3 2024, and $37.0 million in Q2 2024.